

# Mild Cognitive Impairment

*Diagnostic and Therapeutic Issues*


October 1-2, 1999

*The Ritz-Carlton,  
St. Louis*

*St. Louis,  
Missouri*

*"Experts in the field say a condition known as mild cognitive impairment (MCI), which precedes development of AD and other dementias in many people, appears to be a signal of disease onset that will help target individuals for early interventions."*

Friedrich MJ. *JAMA*.  
1999;282(7):621.



## *2nd Leonard Berg Symposium* on Alzheimer's Disease

 **Washington**  
WASHINGTON UNIVERSITY IN ST. LOUIS  
School of Medicine



# Dear Colleague:

Please accept my personal invitation to attend the 2nd Leonard Berg Symposium on Alzheimer's Disease. This year's program is entitled **Mild Cognitive Impairment: *Diagnostic and Therapeutic Issues*** and complements the mild cognitive impairment (MCI) meeting held earlier this year as reported in *JAMA* (1999;282[7]:621-622). This invaluable program will examine MCI, covering topics such as diagnostic issues, clinical course, neuroimaging, and treatment. This program is made possible through an unrestricted educational grant from the U.S. Pharmaceuticals Group, Pfizer Inc, and Eisai Inc. and is sponsored by the Alzheimer's Disease Research Center of Washington University School of Medicine.

The meeting will be held October 1-2, 1999, in Clayton (near St. Louis), Missouri, at The Ritz-Carlton, St. Louis. To register for this program, please return the attached business reply card or call 1-800-835-7633. Seating is limited; please register as soon as possible.

I look forward to sharing this information with you and obtaining your feedback on the issues presented.

Respectfully,

*John C. Morris, MD*

**John C. Morris, MD**  
Program Chairman

## Faculty

**John C. Morris, MD**  
*Chairman*

Harvey A. and Dorismae Hacker Friedman  
Professor of Neurology  
Washington University School of Medicine  
Department of Neurology  
St. Louis, Missouri

**Marilyn S. Albert, PhD**  
Professor of Psychiatry  
Director of Neurology  
Harvard Medical School  
Boston, Massachusetts

**Steven T. DeKosky, MD**  
Professor of Psychiatry, Neurology,  
and Neurobiology  
University of Pittsburgh Medical Center  
Pittsburgh, Pennsylvania

**David Knopman, MD**  
Professor, Associate Head  
Department of Neurology  
University of Minnesota Medical School  
Minneapolis, Minnesota

**Ronald C. Petersen, MD, PhD**  
Professor of Neurology  
Mayo Clinic and Foundation  
Rochester, Minnesota


**Eric Reiman, MD**  
Professor and Associate Head of Psychiatry  
University of Arizona  
Tucson, Arizona

**Martin Rossor, MA, MD, FRCP**  
Dementia Research Group  
National Hospital for Neurology  
and Neurosurgery  
London, United Kingdom

**Peter Seubert, MD**  
Elan Pharmaceuticals  
South San Francisco, California

**Martha Storandt, PhD**  
Department of Psychology  
Washington University  
St. Louis, Missouri

**Leon J. Thal, MD**  
Florence Riford Chair in  
Alzheimer's Disease  
Professor of Neurosciences  
University of California  
San Diego, California



# Agenda

Friday, October 1, 1999

- 8:30 AM *Opening Remarks*  
John C. Morris, MD
- SESSION I  
**Mild Cognitive Impairment: Relationship to Aging and Incipient Alzheimer's Disease (AD)**
- 9:00 *Characterization of Mild Cognitive Impairment (MCI)*  
Ronald C. Petersen, MD, PhD
- 9:30 Question and Answer Session
- 9:40 *Cognitive Function in Nondemented Aging*  
Martha Storandt, PhD
- 10:10 Question and Answer Session
- 10:20 Break
- 10:40 *Incipient AD: Clinical Detection*  
John C. Morris, MD
- 11:10 Question and Answer Session
- 11:20 Panel Discussion
- 11:50 Lunch
- SESSION II  
**Are We Ready To Treat MCI?**
- 12:50 PM *Trial Designs and Therapeutic Agents for MCI*  
Leon J. Thal, MD
- 1:20 Question and Answer Session
- 1:30 *Cholinesterase Inhibitors in MCI*  
Steven T. DeKosky, MD
- 2:00 Question and Answer Session
- 2:10 Break
- 2:30 *Anti-amyloid Therapeutic Strategies*  
Peter Seubert, MD

- 3:00 Question and Answer Session
- 3:10 *Are We Ready To Treat MCI? A Clinical Perspective*  
David Knopman, MD
- 3:40 Question and Answer Session
- 3:50 Panel Discussion/Consensus Statement
- 4:20 Reception

Saturday, October 2, 1999

- SESSION III  
**Neuroimaging in MCI**
- 9:30 AM *Structural Neuroimaging and Cognitive Measures in Individuals at Risk for Familial AD*  
Martin Rossor, MA, MD, FRCP
- 10:00 Question and Answer Session
- 10:10 *Assessing AD in the Absence of Symptoms Using Functional Neuroimaging*  
Eric Reiman, MD
- 10:40 Question and Answer Session
- 10:50 Break
- 11:10 *Relating Neuroimaging to Neuropsychological Function in the Detection of Incipient AD*  
Marilyn S. Albert, PhD
- 11:40 Question and Answer Session
- 11:50 Panel Discussion
- 12:20 PM Closing Remarks  
John C. Morris, MD
- 12:30 Adjourn